Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Isaacs, MD
John T. Isaacs, Pheonix, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20080247950 | Activation of peptide prodrugs by hK2 - The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention. | 10-09-2008 |
| 20110245147 | Activation of Peptide Prodrugs by HK2 - The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention. | 10-06-2011 |
John T. Isaacs, Phoenix, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20100120697 | Tumor Activated Prodrugs - The instant invention provides compositions comprising a prodrug, the prodrug comprising a therapeutically active drug; and a peptide selected from the group consisting of the sequences: Ser-Ser-Lys-Tyr-Gln (SEQ ID NO:1); Gly-Lys-Ser-Gln-Tyr-Gln (SEQ ID NO:2); and Gly-Ser-Ala-Lys-Tyr-Gln (SEQ ID NO:3) wherein the peptide is linked to the therapeutically active drug to inhibit the therapeutic activity of the drug, and wherein the therapeutically active drug is cleaved from the peptide upon proteolysis by an enzyme having a proteolytic activity of prostate specific antigen (PSA). The invention further provides methods of making and using the claimed compositions. | 05-13-2010 |
| 20100234300 | PROAEROLYSIN CONTAINING PROTEASE ACTIVATION SEQUENCES AND METHODS OF USE FOR TREATMENT OF PROSTATE CANCER - Disclosed herein are modified proaerolysin (PA) peptide. In some examples, the proteins include a prostate-specific protease cleavage site and can further include a prostate-tissue-specific binding domain which functionally replaces the native PA binding domain. In other examples, the proteins include a furin cleavage site and a prostate tissue-specific binding domain which functionally replaces the native PA binding domain. Methods of using such peptides to treat prostate cancer are also disclosed. | 09-16-2010 |
John Thomas Isaacs, Phoenix, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20120093724 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CANCER - Various embodiments of this invention relate generally to targeted activation and delivery of therapeutic drugs to cells that produce prostate specific antigen (PSA), prostate specific membrane antigen (PSMA) or human glandular kallikrein (hK2). Various further embodiments relate more specifically to PSMA-specific peptide prodrugs that become activated to yield therapeutic drugs. Further aspects of various embodiments of the present invention also relate to methods and compositions for treating or preventing cancers and methods and compositions for detecting and/or imaging cancers. | 04-19-2012 |
John Todd Isaacs, Phoenix, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20090163426 | TISSUE SPECIFIC PRODRUGS - The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific membrane antigen (PSMA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSMA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSMA, the therapeutic drugs are activated and exert their toxicity. Sesquiterpene-γ-lactones form part of the prodrugs, and are designed to be linked to carrier moieties such as the peptides of the invention. Methods for treating cell proliferative disorders are also featured in the invention. | 06-25-2009 |
Lyle David Isaacs, Beltsville, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20090072191 | Nor-Seco-Bis-Nor-Seco, Tris-Nor-Seco, and Higher Nor-Seco-Cucurbit[n]Uril Compounds - Nor-seco-type cucurbit[n]uril compounds and methylene bridged glycoluril oligomers are produced by reacting glycoluril and formaldehyde in strong organic or mineral acid at a temperature adequate to condense the reactants. These compounds are characterized by lacking —CH | 03-19-2009 |
Lyle David Isaacs, Bethesda, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20100010215 | Introverted CB[N] Compounds - Inverted cucurbituril compounds having at least one pair of hydrogen atoms protruding into an internal molecular cavity thereof. | 01-14-2010 |
William Isaacs, Glyndon, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20110110926 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PROSTATE CANCER AND FOR DETECTING ANDROGEN RECEPTOR VARIANTS - The invention features diagnostic and therapeutic methods and compositions featuring androgen receptor variant proteins and nucleic acid molecules whose expression is increased in androgen related diseases or disorders. | 05-12-2011 |
William B. Isaacs, Glyndon, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20100047809 | PCA3, PCA3 GENES, AND METHODS OF USE - The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal. | 02-25-2010 |
| 20100267024 | MUTATIONS IN THE MACROPHAGE SCAVENGER RECEPTOR 1 GENE ALTER RISK OF PROSTATE CANCER, ASTHMA, AND CARDIOVASCULAR DISEASE - The present invention discloses methods of screening a subject for increased likelihood or risk of certain diseases or disorders. This method comprises detecting the presence or absence of at least one mutation in the MSR1 gene wherein the presence or absence of such mutation indicates an increased risk for certain diseases, such as cancer asthma and/or cardiovascular diseases. | 10-21-2010 |